Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,912 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bleeding Disorder Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial

NCT03584854
View directory record Official record
Conditions
Postpartum Hemorrhage, Uterine Atony
Interventions
15-methyl prostaglandin F2α, Methylergonovine Maleate
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 21, 2026, 6:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers

NCT01589666
View directory record Official record
Conditions
Coagulation Defects
Interventions
Spray-dried S/D-treated Plasma, Spray-dried S/D-treated plasma
Biological · Drug
Lead sponsor
Entegrion, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 21, 2026, 6:32 AM EDT
Not listed Phase 2 Interventional

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

NCT00107913
View directory record Official record
Conditions
Autoimmune Thrombocytopenic Purpura
Interventions
Doxil
Drug
Lead sponsor
Hematology and Oncology Specialists
Other
Eligibility
0 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 6:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

NCT01486927
View directory record Official record
Conditions
Hemophilia A
Interventions
rVIII-SingleChain, Octocog alfa
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Sacramento, California • San Diego, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 21, 2026, 6:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Abdominal Ultrasound Assessment in the Post-cesarean Patient

NCT02159105
View directory record Official record
Conditions
Postpartum Hemorrhage, Postsurgical Bleeding, Abdominal Ultrasound, FAST Scan, Non-invasive Hemoglobin Measurement
Interventions
FAST scan and non-invasive hemoglobin measurement
Device
Lead sponsor
Northwestern University
Other
Eligibility
12 Years to 60 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 21, 2026, 6:32 AM EDT
Completed Phase 4 Interventional Results available

Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage

NCT02330094
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 21, 2026, 6:32 AM EDT
Completed Not applicable Interventional

Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty

NCT01583465
View directory record Official record
Conditions
Osteoarthritis, Hip, Joint Deformities, Acquired, Hip Dislocation, Congenital, Osteonecrosis, Arthritis, Rheumatoid
Interventions
Aquamantys, standard electrocautery (Bovie)
Device
Lead sponsor
Joint Implant Surgeons, Inc.
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Albany, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 21, 2026, 6:32 AM EDT
Recruiting No phase listed Observational

Depth of Maximal Ileal Insertion During Retrograde Enteroscopy With TTS Balloon

NCT04646083
View directory record Official record
Conditions
Obscure Gastrointestinal Bleeding, Anemia, Iron Deficiency
Interventions
Not listed
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 21, 2026, 6:32 AM EDT
Terminated Phase 4 Interventional Results available

Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures

NCT03361137
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 21, 2026, 6:32 AM EDT
Completed Phase 4 Interventional Results available

Time Interval for Endoscopic Variceal Ligation

NCT01291277
View directory record Official record
Conditions
Variceal Bleeding
Interventions
Endoscopic Variceal Ligation
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 21, 2026, 6:32 AM EDT
Terminated Phase 1 Interventional

Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

NCT00244257
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
GMA161
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 21, 2026, 6:32 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04224688
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
St. Petersburg, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 21, 2026, 6:32 AM EDT
Terminated Phase 4 Interventional Results available

INdividualized ITI Based on Fviii(ATE) Protection by VWF

NCT03204539
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia A
Interventions
Wilate
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Sacramento, California • San Diego, California • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 21, 2026, 6:32 AM EDT
Completed No phase listed Observational

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

NCT03876301
View directory record Official record
Conditions
Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, Hemophilia A, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, Hematologic Diseases, Hemorrhagic Disorders, Factor VIII Deficiency
Interventions
Standard of Care FVIII Replacement therapy
Drug
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Timeline
2019 – 2023
U.S. locations
6
States / cities
San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 21, 2026, 6:32 AM EDT
Completed Phase 4 Interventional Results available

Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia

NCT01165307
View directory record Official record
Conditions
Menorrhagia
Interventions
Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
Drug · Device
Lead sponsor
Abimbola Famuyide
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 21, 2026, 6:32 AM EDT
Completed Phase 4 Interventional Results available

Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery

NCT00958581
View directory record Official record
Conditions
Scoliosis
Interventions
Tranexamic Acid, Normal Saline, Epsilon aminocaproic acid
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
10 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 21, 2026, 6:32 AM EDT
Not listed Not applicable Interventional

Defining the Operating Characteristics of NIRS in the Diagnosis of Pediatric Traumatic Intracranial Hemorrhage

NCT03905031
View directory record Official record
Conditions
Craniocerebral Injuries, Head Injuries, Head Injury, Minor, Head Trauma, Traumatic Brain Injury, Traumatic Brain Hemorrhage, Hematoma of Head, Intracranial Hemorrhages
Interventions
InfraScanner 2000
Device
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 21, 2026, 6:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

NCT00157157
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 6 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
17
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 21, 2026, 6:32 AM EDT
Recruiting Not applicable Interventional

Lateral Pharyngoplasty Outcomes in Children Undergoing Tonsillectomy

NCT05575401
View directory record Official record
Conditions
Sleep-Disordered Breathing, Sleep Apnea Syndromes in Children, Sleep Apnea, Obstructive, Tonsillitis, Tonsillar Hypertrophy, Tonsil Stone, Tonsil Disease
Interventions
Lateral pharyngoplasty, Tonsillectomy
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
3 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Murrieta, California • Riverside, California • San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 21, 2026, 6:32 AM EDT
Completed Phase 1 Interventional

Tipifarnib in Treating Patients With Advanced Hematologic Cancer

NCT00005967
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 21, 2026, 6:32 AM EDT
Terminated No phase listed Observational

A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone

NCT02050581
View directory record Official record
Conditions
Idiopathic Thrombocytopenia Purpura
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
3 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 21, 2026, 6:32 AM EDT
Completed No phase listed Observational

The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study

NCT02371330
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Not listed
Lead sponsor
Karolinska Institutet
Other
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 21, 2026, 6:32 AM EDT
Not listed No phase listed Observational

Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery

NCT00653601
View directory record Official record
Conditions
Bleeding, Thrombosis
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Oct 21, 2026, 6:32 AM EDT
Completed No phase listed Observational

Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia

NCT03185897
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Non-treatment, seroprevalence
Other
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • East Lansing, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 21, 2026, 6:32 AM EDT